Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_2
3
75%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Terminated(3)

Detailed Status

Terminated2
Completed1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 23 (75.0%)

Trials by Status

completed125%
terminated250%
withdrawn125%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_2

Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma

NCT00667628
terminatedphase_2

Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy

NCT00687596
withdrawnphase_2

A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma

NCT00756782
completedphase_1

TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

NCT00077142

Clinical Trials (4)

Showing 4 of 4 trials
NCT00667628Phase 2

Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma

Terminated
NCT00687596Phase 2

Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy

Terminated
NCT00756782Phase 2

A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma

Withdrawn
NCT00077142Phase 1

TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4